Showing 970 – 980 of 1159 results
-
ManpowerGroup Inc Initiation
William Blair initiated research coverage of ManpowerGroup Inc. (MAN $77.68), a leading global provider of staffing services and other talent solutions.
-
Enfusion Inc Initiation
William Blair initiated research coverage of Enfusion, Inc. (ENFN $22.52), a leading provider of SaaS-based investment operations management software.
-
InnovAge Holding Corp Initiation
William Blair & Company initiated research coverage of InnovAge Holding Corp. (INNV $24.35), the largest PACE operator in the country. The company coordinates and delivers all-inclusive, capitated care to dual-eligible seniors in five states through its 18 care centers, participant homes, and third-party providers.
-
Rackspace Technology Inc Initiation
William Blair & Company initiated research coverage of Rackspace Technology, Inc. (RXT $23.78), a leading end-to-end multicloud technology services company. Rackspace designs, builds, and operates its customers’ cloud environments across all major technology platforms, irrespective of technology stack or deployment model.
-
Confluent Inc Initiation
William Blair initiated research coverage of Confluent, Inc. (CFLT $81.93), which provides event stream processing and data management solutions to enterprise customers.
-
Solo Brands Inc Initiation
William Blair initiated research coverage of Solo Brands, Inc. (DTC $18.60). Solo Brands is rapidly growing DTC platform of lifestyle brands including Solo Stove, Chubbies, Oru Kayak, and Isle.
-
Udemy Inc Initiation
William Blair initiated research coverage of Udemy, Inc. (UDMY $30.97), an open-source learning content provider for both individual learners and businesses.
-
GitLab Inc Initiation
William Blair initiated research coverage of GitLab, Inc. (GTLB $119.03). GitLab provides an end-to-end DevOps platform to businesses globally.
-
MiNK Therapeutics Inc Initiation
William Blair initiated research coverage of MiNK Therapeutics, Inc. (INKT $17.38). MiNK Therapeutics is focused on the development of invariant natural killer T (iNKT) cell-based therapies for the treatment of cancers and autoimmune diseases.
-
Stevanato Group Initiation
William Blair initiated research coverage of Stevanato Group S.p.A. (STVN $20.62), a leading global provider of drug containment solutions, diagnostic consumables, and drug delivery systems to the pharmaceutical, biotechnology, and life sciences industries.